Exceptional Response to Trastuzumab Deruxtecan in a Patient With Recurrent Ovarian Clear Cell Carcinoma With Human Epidermal Growth Factor Receptor 2 Expression
0
Authors
Ben Kong
Ben Kong•Jayne Stommel•Tanja Pejović
Published
June 1, 2024
Abstract
Case report of a HER2-expressed ovarian clear cell carcinoma with exceptional response to trastuzumab deruxtecan.
